Treatment of macrophage-related disorders

Patent metadata

Field	Value
Publication number	US-9579346-B2
Application number	US-201414271054-A
Country	US
Kind code	B2
Filing date	May 6, 2014
Priority date	Aug 6, 2009
Publication date	Feb 28, 2017
Grant date	Feb 28, 2017

Abstract

The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.

First claim

What is claimed is:

1. A sodium chlorite compound, wherein said compound is a crystalline solid of greater than 95% purity; wherein said compound has an x-ray powder diffraction pattern with peaks expressed in degrees 2θ at about 21, 30, 32, 34, and 39; and wherein said compound has an x-ray powder diffraction (XRPD) pattern as shown in FIG. 6 .

2. A compound of claim 1 , wherein said compound is a crystalline solid of greater than 99% purity.

3. A compound of claim 1 , wherein said compound is a crystalline solid of greater than 99.9% purity.

4. The compound of claim 1 , wherein said compound is substantially free of chlorate.

5. The compound of claim 1 , wherein said compound is substantially free of sulfate.

6. A pharmaceutical composition comprising:
a) the compound of claim 1 ;
b) a pH adjusting agent; and
c) a pharmaceutically acceptable excipient or carrier;
wherein said composition is a liquid that exhibits 25% less pH drift compared to an identical composition without said pH adjusting agent.

7. The composition of claim 6 , wherein said pH adjusting agent is sodium phosphate dibasic.

8. The composition of claim 6 , wherein said compound is substantially free of chlorate.

9. The composition of claim 6 , wherein said compound is substantially free of sulfate.

10. A solid pharmaceutical composition comprising:
a) the compound of claim 1 ; and
b) a pharmaceutically acceptable excipient or carrier.

11. The composition of claim 10 , wherein said compound is substantially free of chlorate.

12. The composition of claim 10 , wherein said compound is substantially free of sulfate.

13. A method of treating a disease associated with migration of monocytes or activated macrophages, said method comprising administering a therapeutically-effective amount of the compound of claim 1 .

14. The method of claim 13 , wherein said disease is characterized by elevated CD16 expression levels in CD14+cells.

15. The method of claim 13 , wherein said disease is characterized by migration of PBMCs in response to a chemoattractant.

16. A method of treating a disease associated with excess activation of monocytes to activated macrophages, said method comprising administering a therapeutically-effective amount of the compound of claim 1 .

17. The method of claim 16 , wherein said disease is associated with excess CD14CD16 expression.

18. The method of claim 16 , wherein said disease is a neurodegenerative disease selected from the group consisting of amyotrophic lateral sclerosis (ALS), Parkinson's Disease (PD), Alzheimer's Disease (AD), and complications thereof.

19. A method of treating Type II diabetes or related complications comprising administering to a subject in need thereof an effective amount of the compound of claim 1 .

Assignees

• Neuraltus Pharmaceuticals Inc
• Univ California
• The Regents Of The Univerity Of California

Inventors

• Mcgrath Michael S
• Azhir Arasteh Ari

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title